Skip to main content
Premium Trial:

Request an Annual Quote

Cardio Test Developer Aviir Raises Additional $10M

NEW YORK (GenomeWeb News) – Irvine, Calif.-based Aviir announced yesterday that it has raised $10 million in a second tranche of a private financing round.

The firm, which is developing multiplex protein-based diagnostics tests for cardiovascular conditions, had already raised $10 million and expects to bring in a total of $30 million in the financing.

Proceeds from the financing will be used to fund the US launch of its MIRISK VP cardiac risk assessment technology and additional lab tests services provided through its Aviir Diagnostic Laboratories. The MIRISK VP technology measures the blood levels of seven proteins associated with the development of vulnerable plaque and then uses a complex algorithm to analyze those results and other known risk factors to determine an individual’s probability of experiencing a heart attack within the next five years, said Aviir.

The financing round was led by the Merck Global Health Innovation Fund, which was joined by Partners & Partners as an investor. The firm's other current investors, including Bay City Capital, Aberdare Ventures, and New Leaf Ventures, also participated in the round.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.